BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 12038879)

  • 1. Aromatase inhibitors and inactivators for breast cancer therapy.
    Lønning PE
    Drugs Aging; 2002; 19(4):277-98. PubMed ID: 12038879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of aromatase inactivators in the treatment of breast cancer.
    Lønning PE
    Int J Clin Oncol; 2002 Aug; 7(4):265-70. PubMed ID: 12202980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving role of aromatase inhibitors in breast cancer.
    Mokbel K
    Int J Clin Oncol; 2002 Oct; 7(5):279-83. PubMed ID: 12402060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase inhibitors for treatment of postmenopausal patients with breast cancer.
    Tamaki Y; Miyoshi Y; Kim SJ; Tanji Y; Taguchi T; Noguchi S
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):193-201. PubMed ID: 12722879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
    Goss PE; Strasser K
    Drugs; 2002; 62(6):957-66. PubMed ID: 11929341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letrozole: a review of its use in postmenopausal women with breast cancer.
    Simpson D; Curran MP; Perry CM
    Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
    Dixon JM
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):267-75. PubMed ID: 12113050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Aromatase inhibitors: therapeutic outlook].
    Namer M
    Bull Cancer; 2000 Dec; 87 Spec No():41-5. PubMed ID: 11250607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitors as adjuvant therapy in breast cancer.
    Visvanathan K; Davidson NE
    Oncology (Williston Park); 2003 Mar; 17(3):335-42, 347; discussion 347-50, 354. PubMed ID: 12661266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks versus benefits in the clinical application of aromatase inhibitors.
    Goss PE
    Endocr Relat Cancer; 1999 Jun; 6(2):325-32. PubMed ID: 10731126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to endocrine therapy of breast cancer: recent advances and tomorrow's challenges.
    Geisler J; Lønning PE
    Clin Breast Cancer; 2001 Jan; 1(4):297-308; discussion 309. PubMed ID: 11899352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exemestane and aromatase inhibitors in the management of advanced breast cancer.
    Dixon JM
    Expert Opin Pharmacother; 2004 Feb; 5(2):307-16. PubMed ID: 14996627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the newer aromatase inhibitors in the management of metastatic breast cancer.
    Reddy P
    J Clin Pharm Ther; 1998 Apr; 23(2):81-90. PubMed ID: 9786093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors in breast cancer: an update.
    Lake DE; Hudis C
    Cancer Control; 2002; 9(6):490-8. PubMed ID: 12514567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Aromatase inhibitors in the therapy for breast cancer].
    Lønning PE
    Tidsskr Nor Laegeforen; 2005 Mar; 125(6):723-8. PubMed ID: 15776065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitors as adjuvant treatment of breast cancer.
    Geisler J; Lønning PE
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):53-61. PubMed ID: 16337805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential for aromatase inhibition in breast cancer prevention.
    Lønning PE; Kragh LE; Erikstein B; Hagen A; Risberg T; Schlichting E; Geisler J
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4423s-4428s; discussion 4411s-4412s. PubMed ID: 11916235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.